ArticleThe oncologist2016

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Takahiro Kogawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.